Latest
Science & Space

University of Cincinnati Researchers Uncover Biological and Immune Differences in Pancreatic Cancer Tumors

A peer-reviewed Cancer Research study led by University of Cincinnati Cancer Center scientist Nina Steele mapped tens of thousands of multiomic markers, finding distinct tumor RNA profiles and immunosuppressive B cells across patient populations.

Read the story
Science & Space · Read the story
Newstro Science & Space section banner.
Newstro
Share this story

Multiomic study addresses long-standing diversity gap in pancreatic tumor data

Cincinnati, Ohio — November 17, 2026.

Researchers at the University of Cincinnati Cancer Center have uncovered measurable biological and immune-environment differences inside pancreatic tumors across diverse patient groups, offering new clues into why outcomes vary sharply and how future therapies might be tailored, according to the University of Cincinnati, Fox News, and AOL.

Published in the peer-reviewed journal Cancer Research, the study was led by Nina Steele, Ph.D., an assistant professor in UC’s College of Medicine, in collaboration with Howard Crawford of the Henry Ford + Michigan State University Pancreatic Cancer Center. Using a large-scale multiomic analysis, the team mapped tens of thousands of molecular markers to overcome a historical underrepresentation of diverse cohorts in pancreatic cancer datasets.

Tumor cells and B cells behaved differently across patient cohorts

Because pancreatic cancer develops roughly 20 percent more frequently in Black African Americans than in non-African Americans, investigators compared molecular signatures across groups and found distinct biological patterns rather than uniform tumor behavior, the University of Cincinnati reported.

Cancer cells analyzed from Black patients showed upregulated RNAs and proteins tied to biological pathways associated with drug resistance. At the same time, B cells—key white blood cells inside the surrounding tumor microenvironment—were not only more abundant in those samples but also displayed immunosuppressive traits capable of dampening the body’s immune defenses.

What the findings mean for RAS inhibitors and future trials

In a follow-up interview highlighted by the University of Cincinnati, Steele emphasized that understanding how tumors adapt across different populations could improve patient forecasting and guide next-generation targeted drugs, including emerging RAS and KRAS inhibitors.

Researchers cautioned that the discovery marks an early biological map rather than an immediate clinical test: larger prospective studies and clinical trials will be needed to confirm whether modifying treatment regimens based on these molecular and immune-cell profiles improves survival rates.

University of Cincinnati Cancer Center and College of Medicine

Steele’s laboratory is based at the University of Cincinnati College of Medicine and the University of Cincinnati Cancer Center in Cincinnati’s medical corridor.

★ Cincinnati, OH — University of Cincinnati College of Medicine and Cancer Center. Map data: OpenStreetMap contributors.

Research publication and national coverage timeline

  1. — University of Cincinnati announces Steele’s multiomic pancreatic cancer study published in Cancer Research.
  2. — UC highlights follow-up broadcast interviews detailing the tumor immune-environment findings and personalized treatment potential.
  3. — National health outlets spotlight the team’s unexpected B-cell and drug-resistance marker discoveries.